Application of combination of benzoylaconitine and paeoniflorin to preparation of drug used for treating rheumatoid arthritis

A technology of benzoylaconitine and therapeutic drugs, which is applied in the field of medicine and can solve the problems of high toxic and side effects and affecting patients' medication compliance

Inactive Publication Date: 2018-11-16
SICHUAN PROVINCIAL PEOPLES HOSPITAL
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The main therapeutic drugs include non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, disease-modifying antirheumatic drugs (DMARDs),

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of combination of benzoylaconitine and paeoniflorin to preparation of drug used for treating rheumatoid arthritis
  • Application of combination of benzoylaconitine and paeoniflorin to preparation of drug used for treating rheumatoid arthritis
  • Application of combination of benzoylaconitine and paeoniflorin to preparation of drug used for treating rheumatoid arthritis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Study on the pharmacodynamic effect of benzoylaconitine combined with paeoniflorin on collagen-induced arthritis (CIA)

[0029] (1) Experimental animals

[0030] SD rats, male, weighing (140±10) g, were provided by the Institute of Experimental Animals, Sichuan Academy of Medical Sciences Sichuan Provincial People's Hospital, production license number: SCXK (Sichuan) 2013-15.

[0031] All experimental rats were adaptively fed for 5 days in the Experimental Animal Center of Sichuan Academy of Medical Sciences before the experiment. Breeding environment: temperature 22°C to 23°C, humidity 30% to 50%; feeding method: divided into cages according to groups, 5 birds per cage, free to eat and drink.

[0032] (2) Experimental drug and liquid preparation

[0033] (2.1) Experimental drugs

[0034] Benzoylaconitine, developed by Chengdu Mansite Biotechnology Co., Ltd. and Chengdu Institute of Biology, Chinese Academy of Sciences, purity: 99.96% (HPLC), batch number: MUST-16012...

Embodiment 2

[0093] Mechanism of benzoylaconitine combined with paeoniflorin in the treatment of collagen-induced arthritis

[0094] (1) experimental animals, (2) preparation of experimental medicine and medicinal liquid, same as in Example 1;

[0095] (3) Main experimental reagents

[0096] Bovine type II collagen solution (2mg ml-1), produced by Chondrex Company of the United States, batch number: SLBR1681V;

[0097] Complete Freund's Adjuvant (CFA), produced by Sigma, USA, batch number: 160346;

[0098] Rat interleukin 1β (IL-1β) ELISA kit, produced by Wuhan Elabscience, batch number: AK0016DEC23031;

[0099] Rat tumor necrosis factor α (TNF-α) ELISA kit, produced by Wuhan Elabscience, batch number: AK0016DEC23032

[0100] Rat VEGF ELISA kit, produced by Xinbosheng Biotechnology Co., Ltd., batch number R161221-103a

[0101] Rat immunoglobulin G (IgG) ELISA kit, produced by Wuhan Elabscience, batch number: AK0017JAN12020

[0102] Rat prostaglandin E2 (PGE2) ELISA kit, produced by Wu...

Embodiment 3

[0152] Embodiment 3 medicine embodiment

[0153] Take benzoylaconitine and paeoniflorin, according to the dosage ratio of 0.1-2.0:24 (unit: mg·kg -1 d -1 ) after dissolving, add other pharmaceutically acceptable ingredients, including excipients, excipients, etc., according to the existing pharmaceutical technology to make capsules, tablets, microcapsules, oral agents and / or injections, preferably Oral preparations or injections, thereby preparing a rheumatoid arthritis treatment drug.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention specifically discloses application of a combination of benzoylaconitine and paeoniflorin to preparation of a drug used for treating rheumatoid arthritis, and the prepared drug, belongingto the field of medicines. According to the invention, the combination of benzoylaconitine and paeoniflorin benzoyl aconitine exerts the synergistic multiple-effect functions of eliminating inflammations, easing pain, alleviating the synovial hyperplasia of joints, inhibiting the formation of pannus, reducing the infiltration of inflammatory cells and reducing bone destruction and/or pathologicalchanges of ankle joints by inhibiting the generation of serum PGE2, regulating serum cytokines (IL-1beta, TNF-alpha and VEGF), inhibiting the synthesis and secretion of IgG, and/or regulating the expression of STAT1 and STAT3 in a JAK-STAT signaling pathway; and the combination has multi-effect-target low-toxicity high-efficiency significant therapeutic effect on rheumatoid arthritis, increases the cure rate of patients with rheumatoid arthritis, and reduces the varieties and dosages of used drug; and application of the combination to the preparation of the drug used for treating rheumatoid arthritis has outstanding significant progressive significance.

Description

technical field [0001] The invention relates to the field of medical inventions, in particular to the use of benzoylaconitine combined with paeoniflorin in the preparation of drugs for treating rheumatoid arthritis. Background technique [0002] Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease with erosive, symmetrical polyarthritis as the main clinical manifestation. The global incidence is about 0.24%, with a high disability rate. The pathogenesis of RA is still unclear. The main pathological features are synovial tissue hyperplasia, inflammatory cell infiltration, and pannus formation, and the destruction of cartilage and bone, which can eventually lead to joint deformity and loss of function. At present, the treatment of RA mainly adopts drugs to relieve joint symptoms, delay the disease, and protect joint function. The main therapeutic drugs include non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, disease-modifying antirheumatic drug...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/439A61K31/7048A61P29/00A61P19/02
CPCA61K31/439A61K31/7048A61P19/02A61P29/00A61K2300/00
Inventor 李晋奇顾平王佳凤童荣生李杰何丹
Owner SICHUAN PROVINCIAL PEOPLES HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap